Open AccessOne-Year Outcomes After MitraClip for Functional Mitral Regurgitation
Author(s) -
Gorav Ailawadi,
D. Scott Lim,
Michael J. Mack,
Alfredo Trento,
Saibal Kar,
Paul Grayburn,
Donald D. Glower,
Andrew Wang,
Elyse Foster,
Atif Qasim,
Neil J. Weissman,
Jeffrey T. Ellis,
Lori Crosson,
Frank S. Fan,
Irving L. Kron,
Paul J. Pearson,
Ted Feldman
Publication year - 2018
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.117.031733
Subject(s) - mitraclip , medicine , functional mitral regurgitation , cardiology , mitral regurgitation , mitral valve , heart failure , ejection fraction
Secondary mitral regurgitation (SMR) occurs in the absence of organic mitral valve disease and may develop as the left ventricle dilates or remodels or as a result of leaflet tethering with impaired coaptation, most commonly from apical and lateral distraction of the subvalvular apparatus, with late annular dilatation. The optimal therapy for SMR is unclear. This study sought to evaluate the 1-year adjudicated outcomes of all patients with SMR undergoing the MitraClip procedure in the EVEREST II (Endovascular Valve Edge-to-Edge Repair Study) Investigational Device Exemption program, which is comprised of the randomized clinical trial, the prospective High-Risk Registry, and the REALISM Continued Access Registry (Multicenter Study of the MitraClip System).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom